• MacroGenics posted a clinical update on its Phase 1 study of MGC026, a B7-H3-directed ADC, in advanced solid tumors.
• Dose escalation tested 1-9 mg/kg every three weeks; 7.5 mg/kg is being evaluated in four tumor-specific cohorts.
• Head and neck squamous cell carcinoma cohort met the Stage 1 response bar; Stage 2 enrollment is underway under Simon’s two-stage design.
• As of July 8, 2026, 74 patients were enrolled; no interstitial lung disease or ocular toxicity was reported.
• Interim Phase 1 results were accepted for an ESMO 2026 poster presentation on Oct. 23 in Madrid.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607231601PRIMZONEFULLFEED9767339) on July 23, 2026, and is solely responsible for the information contained therein.